AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 223 filers reported holding AMICUS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,015 | -1.5% | 412,436 | +1.8% | 0.00% | 0.0% |
| Q2 2023 | $5,089 | +0.4% | 405,340 | -11.3% | 0.00% | +50.0% |
| Q1 2023 | $5,070 | -1.6% | 457,150 | +8.4% | 0.00% | 0.0% |
| Q4 2022 | $5,150 | -99.9% | 421,820 | +4.0% | 0.00% | -60.0% |
| Q3 2022 | $4,233,000 | +2048.7% | 405,521 | +2111.6% | 0.01% | – |
| Q2 2022 | $197,000 | -80.6% | 18,336 | -82.9% | 0.00% | -100.0% |
| Q1 2022 | $1,015,000 | -86.5% | 107,218 | -83.6% | 0.00% | 0.0% |
| Q4 2021 | $7,538,000 | +74.6% | 652,518 | +44.3% | 0.00% | -50.0% |
| Q3 2021 | $4,317,000 | +100.0% | 452,138 | +102.0% | 0.00% | +100.0% |
| Q2 2021 | $2,158,000 | -49.4% | 223,807 | -48.2% | 0.00% | -50.0% |
| Q1 2021 | $4,269,000 | -61.4% | 432,053 | -9.7% | 0.00% | -60.0% |
| Q4 2020 | $11,047,000 | +77.6% | 478,441 | +8.6% | 0.01% | +25.0% |
| Q3 2020 | $6,221,000 | -13.9% | 440,628 | -8.1% | 0.00% | -33.3% |
| Q2 2020 | $7,228,000 | +39.3% | 479,385 | -14.6% | 0.01% | +50.0% |
| Q1 2020 | $5,187,000 | -26.4% | 561,341 | -22.5% | 0.00% | 0.0% |
| Q4 2019 | $7,050,000 | +287.6% | 723,907 | +219.2% | 0.00% | +300.0% |
| Q3 2019 | $1,819,000 | -38.8% | 226,815 | -4.8% | 0.00% | -50.0% |
| Q2 2019 | $2,974,000 | +161.1% | 238,298 | +184.7% | 0.00% | +100.0% |
| Q1 2019 | $1,139,000 | +388.8% | 83,687 | +243.7% | 0.00% | – |
| Q4 2018 | $233,000 | -80.7% | 24,346 | -75.6% | 0.00% | -100.0% |
| Q3 2018 | $1,205,000 | +245.3% | 99,714 | +345.9% | 0.00% | – |
| Q2 2018 | $349,000 | -49.6% | 22,360 | -51.5% | 0.00% | -100.0% |
| Q1 2018 | $693,000 | +50.7% | 46,141 | +44.2% | 0.00% | – |
| Q4 2017 | $460,000 | -81.6% | 32,006 | -80.7% | 0.00% | -100.0% |
| Q3 2017 | $2,504,000 | +2284.8% | 166,032 | +1497.1% | 0.00% | – |
| Q2 2017 | $105,000 | +144.2% | 10,396 | +71.2% | 0.00% | – |
| Q1 2017 | $43,000 | -97.0% | 6,073 | -97.9% | 0.00% | -100.0% |
| Q4 2016 | $1,447,000 | -4.6% | 291,272 | +42.2% | 0.00% | -50.0% |
| Q3 2016 | $1,516,000 | +112.6% | 204,868 | +129.7% | 0.00% | +100.0% |
| Q1 2016 | $713,000 | +366.0% | 89,175 | +423.6% | 0.00% | – |
| Q4 2015 | $153,000 | -64.3% | 17,031 | -48.3% | 0.00% | -100.0% |
| Q3 2015 | $429,000 | +1488.9% | 32,950 | +1637.0% | 0.00% | – |
| Q2 2015 | $27,000 | +145.5% | 1,897 | +70.3% | 0.00% | – |
| Q1 2015 | $11,000 | +83.3% | 1,114 | +58.2% | 0.00% | – |
| Q4 2014 | $6,000 | +500.0% | 704 | +399.3% | 0.00% | – |
| Q3 2014 | $1,000 | -99.2% | 141 | -99.7% | 0.00% | – |
| Q2 2014 | $130,000 | +6400.0% | 43,332 | +3200.2% | 0.00% | – |
| Q1 2014 | $2,000 | +100.0% | 1,313 | +64.7% | 0.00% | – |
| Q4 2013 | $1,000 | -75.0% | 797 | -62.8% | 0.00% | – |
| Q3 2013 | $4,000 | -42.9% | 2,143 | -26.3% | 0.00% | – |
| Q2 2013 | $7,000 | – | 2,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |